Cannabis Canadian and U. S. Priced At $0.01 to $0.99

[Alexulf]

CANNABIS DIVISION
Incorporated in its current form in 2015, MCL draws on over 15 years of licensed cannabis cultivation and genetic development
Low-THC hemp food products approved for sale in Australia
Agreement with Algae.Tec (ASX:AEB) – AEB to give MCL 19.9% of its equity for access to seed bank & expertise
Federal Government announces that it will allow export of Australian medicinal Cannabis products
MCL acquires interest in Hemp Hulling Co., completing seed-tocustomer integration of food business
Nov 17
MCL and CannTab sign JV agreement for Australian and Asian market
John Easterling joins MCL board
Nov 17
Dec 17
Jan 18
Jan 18
First 20 Tonnes of Seed secured for sowing in November with legislation approval
Sep 17
MCL engages the services of EndoCro Ltd, an iCAN Israel-Cannabis company for research and development of medicinal Cannabis products
Oct 17
VitaHemp launches its new Hemp Food Seed
Processing plant expansion to be completed for food products division
Feb 18
MCL completes an agreement to sponsor research into Medical Cannabis Treatments for Multiple Sclerosis with the Research and Development Foundation at the Technion Institute, Haifa, Israel under the leadership of Dr. David (Dedi) Meiri and his team
MCL implements Canntab drug development strategy in conjunction with Certara’s Dr Andreas Wallnoefer and Dr Graham Scott to distribute Canntab XR medication in Australia
MCL first to release Australian Hemp Seed Oil gel Capsules
Feb 18
Mar 18
Apr 18
COLES now selling Hemp Products provided by MCL through Red Tractor
Medcan and MCL acquisitions announced. Medcan is licensed by the ODC for medical Cannabis cultivation and production
Medcan obtains Medical Cannabis import/export licence.
Apr 18
Jun 18
Jul 18
4Q 2018
Dr. David (Dedi) Meiri and his team make a ground breaking discovery identifying a cannabinoid that could lead to potential cure for Multiple Sclerosis (MS)
Aug 18
Nov 17
Review of Operations https://hotcopper.com.au/threads/ann-annual-report-to-shareholders.4501731/#post-36232195